MON-715 Silencing Hepatokine Activin E Production in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile

Wei Liu, Hsiu‐Chiung Yang, Keith Bowman, Stearne Briem, Michael Byrne, Cynthia Caracta, Jigar Desai, Anamitra Ghosh, Naoki Iwamoto, Kandasamy Pachamuthu, Tomomi Kawamoto, Anthony Lamattina, Ken Longo, Khoa Luu, Subramanian Marappan, N. Padma, Leah A. Owen, Priyanka Shiva Prakasha, Jeanette Rheinhardt, Denise J. Schwahn, Himali Shah, Kuldeep Singh, Stephany M. Standley, Kris Taborn, Chandra Vargeese, Erik IngelssonJournal of the Endocrine Society 2025 · DOI

Abstract

Abstract Disclosure: W. Liu: None. H. Yang: None. K. Bowman: None. S. Briem: None. M. Byrne: None. C. Caracta: None. J. Desai: None. A. Ghosh: None. N. Iwamoto: None. P. Kandasamy: None. T. Kawamoto: None. A. Lamattina: None. K. Longo: None. K. Luu: None. S. Marappan: None. P. Narayanan: None. L. Owen: None. P. Prakasha: None. J. Rheinhardt: None. D. Schwahn: None. H. Shah: None. K. Singh: None. S. Standley: None. K. Taborn: None. C. Vargeese: None. E. Ingelsson: None. INHBE (Inhibin βE) encodes Activin E, a hepatokine that regulates adipocyte lipolysis. Heterozygous INHBE loss-of-function (LoF) carriers have reduced abdominal fat, and reduced risk for type 2 diabetes and coronary artery disease, suggesting that lowering INHBE expression by greater than 50% may restore a healthy metabolic profile in obesity. We investigated the impact of reducing Inhbe expression, via N-acetylgalactosamine-conjugated small interfering RNA (GalNAc-siRNA) targeting Inhbe mRNA (INHBE-00003), on body weight and composition in a diet induced obesity (DIO) mouse model, alone or in addition to semaglutide, a GLP-1 receptor agonist (GLP-1RA). C57BL/6 mice were fed a 60% high-fat diet to model DIO phenotypes and were treated with PBS or INHBE-00003 in PBS, alone or added to daily semaglutide injections. Body weight, fat pad weight, skeletal muscle weight, and adipose inflammation were assessed. By 28 days after a single dose of INHBE-00003, DIO mice weighed 9% less, had 40% less diet-induced visceral adipose mass accumulation, and demonstrated 43% less diet-induced adipocyte enlargement than PBS-treated mice. Infiltration of activated macrophages in visceral adipose tissue was also decreased by up to 68% compared with controls. Quadricep muscle mass was preserved. Overall, DIO mice treated with INHBE-00003 recapitulate human genetic findings for INHBE LoF, supporting the reduction of INHBE expression as means to support healthy weight loss. Activin E appears to regulate body weight through a peripheral mechanism distinct from GLP-1RAs; therefore, we next investigated whether INHBE-00003 could enhance weight loss if added to treatment with the GLP-1 agonist semaglutide. After 28 days of semaglutide, DIO mice weighed 9% less than PBS-treated mice. Adding INHBE-00003 to semaglutide treatment increased weight loss to 18% by day 28, compared with PBS controls. Mice treated with semaglutide for 28 days regained all weight that was lost by day 56, whereas mice also treated with INHBE-00003 on days 21 and 28 maintained weight loss relative to PBS controls. These preclinical data support reducing hepatokine Activin E levels through INHBE siRNA treatment as a potential next-generation anti-obesity agent for patients living with obesity and other metabolic co-morbidities. Wave Life Sciences expects to initiate dosing in the INLIGHT clinical trial for WVE-007, an investigational INHBE GalNAc-siRNA, for the treatment of people living with obesity, in Q1 2025. Presentation: Monday, July 14, 2025
BibTeX
@article{liu2025mon,
  author = {Wei Liu and Hsiu‐Chiung Yang and Keith Bowman and Stearne Briem and Michael Byrne and Cynthia Caracta and Jigar Desai and Anamitra Ghosh and Naoki Iwamoto and Kandasamy Pachamuthu and Tomomi Kawamoto and Anthony Lamattina and Ken Longo and Khoa Luu and Subramanian Marappan and N. Padma and Leah A. Owen and Priyanka Shiva Prakasha and Jeanette Rheinhardt and Denise J. Schwahn and Himali Shah and Kuldeep Singh and Stephany M. Standley and Kris Taborn and Chandra Vargeese and Erik Ingelsson},
  title = {{MON-715 Silencing Hepatokine Activin E Production in Mice Recapitulates Human Genetic Data and Demonstrates Improved Healthy Weight Loss Profile}},
  journal = {Journal of the Endocrine Society},
  year = {2025},
  doi = {10.1210/jendso/bvaf149.050},
}

Loading related content...

Figure